Tags: migraine | headache | fremanezumab | side effects

New Migraine Medicine

By
Tuesday, 09 January 2018 04:42 PM Current | Bio | Archive

Approximately 1 in 10 people experience migraine headaches, and a new study points to hope for these people who suffer from this sometimes debilitating condition.

These severe headaches can last for hours or more and may be accompanied by light or sound sensitivity as well as nausea. 

In a recent study published in the New England Journal of Medicine, investigators looking at the effect of the monoclonal antibody fremanezumab, randomized over 1,000 migraine sufferers into one of three groups that received either an injection of fremanezumab (675 mg the first month and then a placebo at weeks four and eight); monthly treatments of fremanezumab with a starting dose of 675 mg and then 225 mg for the second and third month; or a placebo for all three months. 

More than 43 percent of volunteers taking the lowest dose of the drug fremanezumab and 50 percent of volunteers taking the highest dose experienced approximately half as many migraine headaches.

Side effects from the medication were relatively mild.

© 2018 NewsmaxHealth. All rights reserved.

   
1Like our page
2Share
Dr-Small
Approximately 1 in 10 people experience migraine headaches, and a new study points to hope for these people who suffer from this sometimes debilitating condition.
migraine, headache, fremanezumab, side effects
166
2018-42-09
Tuesday, 09 January 2018 04:42 PM
Newsmax Media, Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved